• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » University of Minnesota licenses cyanide antidote to Vytacera

University of Minnesota licenses cyanide antidote to Vytacera

February 13, 2012
CenterWatch Staff

The University of Minnesota has licensed Sulfanegen, an antidote for cyanide poisoning, to California start-up Vytacera Pharma.

The antidote, developed by the university’s Center for Drug Design, is the first cyanide treatment that is both quick-acting and via intra-muscular injection, as opposed to an intravenous injection that takes 20 minutes to take effect. Cyanide poisoning can result from the inhalation of hydrogen cyanide in smoke when certain plastics and household items are burned.

If approved by the FDA, Vytacera will develop and market Sulfanegen. The treatment could be administered by first responders in the case of a mass casualty emergency, or to victims of smoke inhalation from a house fire.

“Sulfanegen can be administered rapidly by intra-muscular injection, so emergency responders could treat people faster. And it takes far less skill to use an auto-injector than it does for an intravenous injection,” said Steve Patterson, co-inventor and associate director of the university’s Center for Drug Design.

The antidote also functions as a prophylactic, and could protect firefighters or emergency personnel if taken prior to cyanide exposure.

Sulfanegen has rapid approval potential under the FDA Animal Rule, which holds that only animal efficacy experiments and phase I safety clinical trials are required for regulatory approval; the compound already has demonstrated safety and efficacy in several animal models.

“We intend to move forward as rapidly as financing and regulations permit,” said Jon S. Saxe, chair of Vytacera. “Our goal is to make this important advance available to those in need of it.”

The technology was licensed exclusively to Vytacera by the university’s Office for Technology Commercialization.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing